Organic Active Ingredients TRIZ Cases

These EGFR compounds combine kinase inhibition with ubiquitin-proteasome degradation to address C797S drug resistance in lung cancer.

Cumbersome skull-fixed head frames complicate pediatric brain delivery; frameless stereotaxy supports precise rAAV2-hAADC dosing.

Novel FAAH inhibitor compounds use heteroaryl substitutions to improve solubility and oral bioavailability while preserving therapeutic activity.

Systematically varied substituents on a pyrazolopyrimidine core target PI3Kγ for cancer and immune-related disorders.

See how phased dienogest and slow EE release support contraception at lower EE doses while reducing peak fluctuations and irregular bleeding.

Localized bicarbonate release from hydrogels neutralizes acidic tumor environments, reducing ion trapping and supporting weak-base chemotherapy.

Sugar moieties and hydrophobic units help dendrimer carriers address low uptake and transfection in non-viral delivery.

Functionalized carriers occupy host-cell receptor sites to limit pathogen attachment while delivering drugs to targeted cells with fewer systemic effects.

Defined XRPD, DSC, and TG-FTIR criteria guide scalable production of Compound (I) while preserving purity and reproducibility across crystalline forms.

Rapid 5-HTP absorption can cause short exposure and peak-related adverse events; a gastroretentive bilayer releases 5-HTP and carbidopa in parallel.

HTR2C polymorphism testing helps identify likely antipsychotic responders, supporting treatment selection for schizophrenia and bipolar disorder.

A universal guide RNA redirects one Cas9 complex to multiple genomic positions, improving setup and scalability for nucleotide-repeat editing.

Lyophilized lipid complexes combine rapid onset with sustained anesthetic release for pain relief across the 2–4-day postsurgical window.

Heterocyclic and cycloalkyl features tune KHK inhibitors to regulate fructose metabolism while limiting tissue asymmetry and toxicity.

Structural diversification of Formula I inhibitors targets the conserved SARS-CoV-2 main protease against mutating coronaviruses.

Subcutaneous injection limits ease of administration; these GLP-1R agonist compounds offer oral or other non-invasive routes while stimulating insulin.

Combining rapamycin with metformin enhances mTORC1 inhibition, enabling lower rapamycin dosing to reduce long-term side effects.

Enteral delivery uses milk-derived exosomes to carry miRNA and TGF-β to intestinal cells, reducing inflammation and avoiding parenteral risks.

Solvent recrystallization develops piperazine crystal forms with improved solubility and stability for pharmaceutical formulation.

Staufen1-regulating agents target RNA metabolism dysregulation to improve autophagy and reduce toxic protein aggregates.

RepSox and staged BMP4, Activin A, FGF2, and VEGF signaling generate contractile SMCs while limiting phenotype switching and restenosis.

Methotrexate’s limited efficacy and liver and gastrointestinal toxicity are addressed by combining it with pimozide for rheumatoid arthritis.

See how pyridinylpyrimidine inhibitors covalently target FGFR4 Cys552 to improve selectivity and antitumor activity over promiscuous kinase inhibition.

Gel strength enhancers and surfactants create controlled API release, supporting sustained therapeutic levels while reducing injection frequency.

Poor cell entry and off-target kinase activity limit older aldolase inhibitors; these salts target aldolase selectively while activating AMPK.

Selective CHK1 inhibition uses substituted pyrazole-heteroaryl compounds to pursue antitumor activity while reducing hepatotoxicity and hemocyte toxicity.

Novel acetamidylthio β-D-galactopyranoside derivatives inhibit galectin-3 binding to natural carbohydrate ligands for disease treatment.

A pressurized aqueous nanoemulsion uses tuned surfactant, alcohol, and lipophilic ratios to preserve vesicle size across temperature stress.

Conventional rAAVs often require high doses for non-liver tissues; engineered muscle-targeting moieties improve delivery while reducing liver toxicity.

Segmented gene panels sequence relevant hereditary cancer genes to balance risk-assessment precision, processing time, and sequencing complexity.

Natural-material variation can destabilize formula efficacy; defined active-ingredient ranges and HPLC testing improve batch consistency.

Novel heterocyclic derivatives modify BCL-2 inhibitor structure to improve solubility and bioavailability while preserving tumor-regression activity.

Modified Formula I compounds target α4β3δ GABAA receptors as positive allosteric modulators for CNS-related disorders.

Cyclophellitol-inspired pseudo-disaccharides target HPSE with nanomolar potency while limiting pleiotropic off-target effects.

Low GLP-1 permeability limits oral bioavailability; this SNAC-salt composition promotes gastrointestinal absorption while improving dissolution and stability.

Dense tumor stroma can block nanoparticle uptake; FAK-siRNA priming helps CRISPR editors reach tumors for gene editing.

Delgocitinib cream targets JAK3-mediated inflammatory signaling in FFA through a simple topical treatment approach.

Anti-CD2 antibodies and donor bone marrow induce transient mixed chimerism to support graft tolerance without long-term immunosuppression.

Sickle cell blockages and impaired blood flow are addressed by isoquercetin, vitamins B3 and C, and optional folic acid targeting PDI.

Resistance to single-kinase treatments is addressed with diaryl macrocycles that inhibit MET, ALK, AXL, TRK, JAK, and ROS1 signaling.

A lipid-based oral composition transports therapeutic agents across the blood-brain barrier to support brain health and function.

Small-molecule cGAS inhibitors curb inflammatory cytokine production to limit chronic inflammation and tissue damage.

Retinoic acid structural changes support neurite growth and neural cell regeneration while maintaining low cytotoxicity.

Novel substituted glucocorticoid compounds and prodrugs modulate receptor activity to expand treatment options for autoimmune and inflammatory diseases.

Esterifying CBDA at its carboxylic acid group improves stability while supporting treatments for joint, skin, gastrointestinal, and metabolic disorders.

Nasal delivery combines creatine fatty esters, omega-3 fatty acids, and glycerides to bypass the blood-brain barrier in CTD.

High humidity destabilizes Compound 1; crystalline fumarate and hemifumarate salts reduce hygroscopicity while preserving purity for storage.

A dual-layer tablet delivers rapid ibuprofen onset and sustained analgesic efficacy for up to 24 hours after administration.

Conventional therapies often miss underlying metabolic dysfunction; MCT1-transported N-acetyl-L-leucine enters cells to balance lactate and support broader symptom relief.

Genistein sensitizes tumor cells to high-LET proton radiation, enabling lower doses while limiting damage to healthy tissues.

Composite Rhaponticum and Rhodiola extracts resolve insufficient muscle mass by stimulating protein synthesis and inhibiting myostatin gene expression.

A 2'-fucosyllactose nutritional composition increases natural killer cell activity and stimulates beneficial gut bacteria.

Modified betulinic acid compounds block viral capsid assembly to prevent infectious particle formation, addressing drug resistance in HIV treatment.

Segmented heterocyclic structures with defined substituents stabilize glutamic acid neurotransmission to treat psychiatric disorders.

Allosteric modulators target the β2-adrenergic receptor to prevent desensitization and adverse effects associated with conventional agonist therapy.

A micronized c-kit kinase inhibitor formulation uses specific particle sizes and crystalline forms to enhance oral bioavailability.

Sigma ligands act as adjuvants to enhance opioid analgesia, reducing required doses and side effects while maintaining effective pain control.

Novel chromene pyridopyrazinedione compounds modulate gamma-secretase activity to reduce amyloid beta protein production.

Bifunctional compounds degrade pathological TDP-43 aggregates to treat neurodegenerative diseases.

TPB binds ZIKV RdRp active sites to inhibit replication, addressing the lack of effective treatments.

Topical apremilast formulations bypass gastrointestinal side effects by delivering the active ingredient directly to affected skin areas.

Immobilizing scavenger functionalities on a macromolecular carrier improves pharmacokinetics and in vivo effectiveness against aldehydes.

Ethanol solvent converts amidine to triazole, reducing recovery time and costs.

A triazolone derivative activates the GPR119 receptor to promote glucose-dependent insulin secretion and enhance metabolic balance.

Targeting venular endothelium reduces local inflammatory responses without causing adverse side effects in healthy tissues.

A pH-sensitive adjuvant carrier delivers antigens to the cytosol of antigen-presenting cells.

Tri-O-acylglycerol suspensions stabilize limus microcrystals to ensure complete drug transfer during short device contact times.

Amphiphilic oligomers self-assemble into adhesive hydrogels to extend drug retention time at the injection site, reducing systemic toxicity.

Administering an anti-HER2 antibody, tucatinib, and a chemotherapeutic agent overcomes resistance mechanisms to achieve synergistic tumor growth inhibition.

Cycloalkyl azetidine compounds target histamine H3 receptors to treat neurological disorders.

Coacervated microencapsulation isolates piperaquine phosphate within a porous polymer shell, preventing degradation of sensitive combination agents.

Ionizable lipids and PEG shield nucleic acids from enzymatic degradation while minimizing immunogenic responses for sustained therapeutic delivery.

Polycyclic Mcl-1 inhibitor compounds overcome cancer drug resistance by inducing apoptosis in tumor cells via optimized molecular binding.

Chiral azabicyclo derivatives target the menin-MLL interface, resolving narrow therapeutic windows in acute leukemia treatment.

Targeting LIMK1 via RNA interference overcomes taxane resistance and reduces systemic toxicity.

Engineered exosomes deliver Argonaute 2 proteins alongside nucleic acid therapeutics, shielding them from RNase degradation and reducing immunogenicity.

Edible wafer composition incorporates fenbendazole within a matrix of natural carbohydrates and visible grain pieces to deliver medication.

Nano lipid carrier encapsulates phenytoin sodium for direct nose-to-brain delivery via the olfactory route.

Formula I compounds inhibit NAMPT in activated B cells while sparing T cells, resolving the trade-off between therapeutic efficacy and cell type specificity.

A superabsorbent polysaccharide network absorbs water to form a porous structure that reduces caloric intake in the gastrointestinal tract.

A crosslinked casein outer layer protects hydrophobic drugs from gastric degradation, enabling targeted intestinal release and improved bioavailability.

Quantifying decidualization rates of cultured stromal cells from menstrual effluent avoids invasive laparoscopic surgery while maintaining diagnostic accuracy.

A microRNA composition induces direct reprogramming of somatic cells into pancreatic beta cells.

Microemulsion based hydrogels enhance benzocaine delivery through a hybrid matrix structure.

Vinyl-substituted heterocyclic linker resolves ADC stability and potency trade-offs by enabling precise thiol-reactive conjugation.

Administering dihydrotestosterone to women with polycystic ovary syndrome and nonalcoholic fatty liver disease.

A ureteral stent integrates a biodisintegrable drug-releasing sleeve to deliver analgesics directly into the urinary tract.

Aryl methyl benzoquinazolinone compounds target the M1 receptor to treat Alzheimer's disease while avoiding peripheral side effects like nausea and diarrhea.

Purified Brucella cyclic beta glucans act as TLR4 agonists to induce dendritic cell maturation and cytokine secretion without triggering endotoxic side effects.

Catalase and anti-inflammatory agents reduce free radical concentrations generated during teeth whitening to prevent oral tissue damage.

Pyrazolo[1,5-a]pyrimidine compounds inhibit cyclin dependent kinases to modulate cellular proliferation and apoptosis.

Phospholipid-mediated delivery of iron(III) reduces pathogenic Proteobacteria while maintaining gut microbiota diversity.

Retinal sequestering compounds bind all-trans-retinal via Schiff base formation to modulate the visual cycle.

Formula I compounds inhibit MAGL enzyme activity, resolving the trade-off between inhibition efficacy and therapeutic versatility for pain management.

Bi-directional gas flow around the nasal septum overcomes congestion barriers, ensuring effective substance deposition in the posterior region.

Combining CYP17A and 5-α-reductase inhibitors blocks multiple androgen synthesis steps to enhance antitumor potency.

Metal bisphosphonate coordination polymer nanoparticles encapsulate chemotherapeutics and nucleic acids within a lipid bilayer shell.

Compounds displace IRP1 from APP mRNA to lower amyloid-beta while preserving iron homeostasis.

Methylated withanolide analogs resolve the contradiction between therapeutic efficacy and toxicity by inhibiting NF-kB while reducing astrogliosis.

Formula I macrocycles neutralize MCL-1 mediated resistance, restoring apoptosis in overexpressing tumors.

A ligase-mediated linker-payload system achieves homogeneous ADC production by resolving the contradiction between coupling efficiency and linker stability.

Benzhydryl derivatives combine PDE4 inhibition and M3 antagonism to reduce systemic side effects while treating COPD.

SK channel activators modulate neuronal excitability to rescue cognitive deficits, balancing therapeutic efficacy with manageable treatment protocols.

Segmented enteric coating protects covalent kinase inhibitors from gastric degradation until reaching the ileum.

Implementing fixed dosing for HER antibodies eliminates weight-based variability to maintain consistent target drug concentrations.

Esterified PAK1 blockers with 1,2,3-triazolyl groups overcome poor bioavailability to treat cancer.

Angelica gigas Nakai extract inhibits platelet aggregation without causing gastrointestinal disorders like gastric ulcers.

A crystalline complex of a glucopyranosyl derivative and L-pyroglutamic acid inhibits sodium-dependent glucose cotransporters.

Redox-activated pro-chelators resolve selective targeting bottlenecks by releasing high-affinity chelators intracellularly to inhibit cell proliferation.

Optimized plume characteristics and isotonicity agents enhance bioavailability, resolving inadequate dosing and stability issues in opioid overdose treatment.

A multilayer osmotic composition uses a placebo layer to generate precise lag time independent of gastric conditions.

Topical erlotinib compositions with penetration enhancers treat palmoplantar keratoderma while minimizing systemic side effects.

Polyether-modified desazadesferrithiocin analogues reduce nephrotoxicity while enhancing oral iron removal.

Sanguisorbae officinalis and Ailanthus altissima extracts upregulate beta-defensin expression in skin keratinocytes.

Phenylazetidinone residues improve pharmacokinetic profiles, extending half-life to reduce dosing levels while maintaining therapeutic efficacy.

Topical taxane nanoparticles in a hydrophobic carrier penetrate cervical tissue, avoiding pain and bleeding from surgical interventions.

Segmented T-cell modulatory polypeptides combine MHC stability with immunomodulatory domains to resolve specificity and complexity trade-offs in cancer therapy.

Nanoparticle compositions deliver nucleic acid agents using dendritic polymer skeletons with controlled PEG moieties to minimize anti-PEG antibody induction.

Replacing blood-derived haptoglobin with cilastatin blocks megalin-mediated hemoglobin uptake, reducing renal injury risk and cost.

Alkaline cross-linking creates shaped hyaluronic acid products with controlled liquid retention and high gel strength, preventing implant migration.

Alkaline pH adjustment in low-water PEG prevents degradation impurities while specific dosing minimizes urothelial toxicity.

Thienodiazepine derivatives selectively inhibit protein kinases to treat abnormal cell growth diseases while reducing side effects.

A simvastatin tablet formulation uses butylhydroxyanisole and citric acid to stabilize the active ingredient.

Conjugate triggers interferon production to resolve payload reliability gaps in cancer immunotherapy.

Sublingual orotic acid tablets absorb rapidly through oral mucosa to increase arterial oxygen saturation levels.

Polysaccharide-rich Bombax costatum extract restores skin barrier integrity and microbiota balance, eliminating irritation from synthetic cosmetic treatments.

Intermittent PTH agonist dosing stimulates matrix synthesis and cellular proliferation, reversing osteoarthritis degeneration.

Oral microparticles release TGF-beta and IL-2 to target regulatory T cells, reducing off-target effects from systemic biologics.

Mutant bacteriophages detect Listeria via genetic modification, reducing detection time from days to under two hours.

N-trans caffeoyltyramine agonists increase mitochondrial mass and fatty acid oxidation to resolve NAFLD treatment contradictions.

Copper-bound CAII boosts nitrite reductase activity to treat hypertension, addressing limited understanding of enzyme efficacy.

Conjugating therapeutic antibodies to beta-1,6-glucan oligomers overcomes limited efficacy across broader cancer types.

Optimized pyridone derivatives replace ineffective interferon treatments by significantly lowering viral markers.

Prodrug nanoparticles dispersed in carrier materials overcome nucleoside analogue incompatibility to provide stable long-acting formulations.

Cationic poly(amine-co-ester) polymers stabilize siRNA against enzymatic degradation while reducing cytotoxicity through optimized hydrophobic monomer content.

Vitamin C acts as an intermediary to stabilize chitosan dispersion, preventing cloudiness and ensuring uniform intake in containerized beverages.

Zn-DTPA intercepts circulating Actinium-225 daughters via chelation, preventing kidney accumulation and mitigating renal toxicity during anti-MUC5AC therapy.

Benzenesulfonamide compounds selectively inhibit NaV1.6 channels, reducing adverse effects from non-selective blockade of NaV1.1 and NaV1.5.

Iron nicotinate complex prevents bathochromic shifts and lipid oxidation, preserving color and flavor stability during heat treatment.

A topical formulation combines botanical extracts and a moisture-retaining polymeric biomaterial to enhance skin hydration.

Recombinant human lysosomal acid lipase with specific glycan structures enables efficient uptake into target cells.